



thetrutides

IPAMORELIN

A selective growth hormone secretagogue

Ipamorelin is valued for what it does *not* do. Earlier growth hormone secretagogues also raised cortisol and prolactin; Ipamorelin was developed to be selective, and that selectivity is the main reason it remains the preferred option in its class.

● In Plain English

Ghrelin is the hormone that makes you hungry, and it also triggers growth hormone release. Older compounds that targeted this system produced both effects, plus unwanted cortisol and prolactin increases. Ipamorelin was engineered to hit the growth hormone trigger cleanly and leave the rest mostly alone.

What people use it for. The same goals as CJC-1295 — recovery, body composition, sleep — and virtually always in combination with it.

What to know before you buy. Ipamorelin's selling point is what it avoids. Earlier compounds in its class also raised cortisol, which is counterproductive if you are trying to recover, and caused significant hunger. Ipamorelin largely does not, at sensible doses. As with the whole growth hormone category, it demonstrably raises the hormone; nobody has demonstrated in controlled trials that this produces the body composition changes people are buying it for.

● What It's Used For

GOAL	WHAT THAT RESTS ON
Growth hormone support	Reliably raises GH in published pharmacological work
No cortisol spike	Selective for GHS-R1a — minimal cortisol, prolactin and ACTH effect at typical doses
No hunger surge	Substantially less appetite stimulation than other ghrelin agonists such as GHRP-6
Pairs with CJC-1295	Separate receptor pathways, so the two add rather than overlap

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.



● How to Buy It

AVAILABLE IN THESE BLENDS

CJC-1295 + Ipamorelin 5mg + 5mg

\$75

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

This compound is supplied as part of the blends above rather than as a standalone vial. **Ships sealed and lyophilized** — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

● At a Glance

CLASS	Pentapeptide; selective ghrelin receptor (GHS-R1a) agonist
MECHANISM	Stimulates pituitary growth hormone release through a different receptor from GHRH analogues, which is why the two are commonly paired
SELECTIVITY	Minimal effect on cortisol, prolactin and ACTH at typical doses — the property that distinguishes it from earlier secretagogues such as GHRP-6
APPETITE	Substantially less appetite stimulation than other ghrelin agonists
REGULATORY (US)	Not FDA-approved. Not on the July 2026 PCAC agenda
FORMAT	Sold in a 5+5mg blend with CJC-1295

5

AMINO ACIDS

GHS-R1a

RECEPTOR TARGET

Selective

MINIMAL CORTISOL / PROLACTIN

REGULATORY STATUS

This compound was **not** on the July 2026 PCAC agenda. Its regulatory status is unchanged by that hearing, and reports about peptides being “cleared” in July 2026 do not apply to it. Treat its status as independent. Ipamorelin remains not FDA-approved and is not on the 503A bulks list.

● Why Selectivity Matters

Cortisol elevation works against most of the reasons people use a growth hormone secretagogue in the first place — it is catabolic, it impairs recovery and it disrupts sleep. Prolactin elevation carries its own unwanted effects. Earlier secretagogues such as GHRP-6 raised both. Ipamorelin’s comparatively clean profile at typical doses is the reason it displaced them.

Why it is paired with CJC-1295

Ipamorelin acts on the ghrelin receptor; CJC-1295 acts on the GHRH receptor. Because they engage separate pathways, the combination is expected to produce a larger release than either alone. This is a reasonable mechanistic

argument — but the combination itself has not been formally studied for outcomes, which is the same caveat that applies to every blend in this range.

● Evidence Position

Ipamorelin reliably raises growth hormone in published pharmacological work; that part is well established. What is not established is that the resulting elevation translates into meaningful changes in body composition, recovery or healthspan in healthy adults. No large controlled outcome trials exist, and it has no approved indication in any major market.

THE BOTTOM LINE

The cleanest-profiled compound in the growth hormone secretagogue category, chosen for selectivity rather than potency. Demonstrated biomarker effect, no demonstrated outcome benefit. Unaffected by the July 2026 hearing.

● Also in the Range

Sold within the **CJC-1295 + Ipamorelin** blend. Ipamorelin alone engages only the ghrelin pathway; the blend adds the GHRH pathway.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** FDA PCAC meeting materials, 23-24 July 2026 (Ipamorelin not on agenda).